Physician profile
Amanda Radford
NPI 1831757368
$454.90
in general payments reported to CMS, 2019-2025
11 companies · $202 in 2025
The $202 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $107 · 2023: $41.10 · 2024: $105 · 2025: $202.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $348.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $347.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $175.63 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $87.01 | 2022-2025 | Airsupra |
| Pfizer INC. | $42.78 | 2024 | |
| Merck Sharp & Dohme LLC | $29.93 | 2023-2024 | Vaxneuvance, Gardasil 9, Gardasil |
| Scilex Pharmaceuticals INC. | $24.33 | 2022 | |
| Organogenesis INC. | $23.36 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.89 | 2025 | Caplyta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.76 | 2025 | Relistor |
| Nevro Corp. | $14.62 | 2024 | Senza |
| Amgen INC. | $13.55 | 2023 | Prolia, Evenity |
| Glaxosmithkline, LLC. | $13.04 | 2023 | Trelegy Ellipta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Radford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.